Coulter Partners secures CEO for George Health Technologies


Coulter Partners was pleased to partner with the George Institute for Global Health to secure the appointment of Phil Offer as Chief Executive Officer of their commercial division, George Health Technologies. Reporting to Staph Leavenworth Bakali, President & CEO of George Health Enterprises, Phil brings extensive leadership experience across multiple sectors that include digital health technology, telco, data analytics and consulting. Based in Sydney, Australia, his primary focus will be to develop the company’s business growth strategy and commercial opportunities.

George Health Technologies has developed a unique digital clinical “intelligent” disease management system for the simultaneous management of multiple non-communicable diseases (NCDs). Utilising sophisticated algorithms that generate evidence-based highly-personalized treatment and care plans, George Health Technologies offers integrated applications for healthcare providers and patients, as well as the knowhow to modify and integrate these algorithms into customer clinical service delivery systems on a digital platform.

Phil Offer is a senior executive with a track record of accelerating growth through the smart adoption of new technology. He has been a proven CEO within digital health since 2013, first with MedicalDirector, Primary Healthcare Ltd and then with management consultancy, Cimbio Group in Australia. Prior to 2013, Phil spent 16 years in senior management roles in the telecoms industry and was Vice President, Mobility and Convergence for Singtel Optus Pty. Phil brings a strong track record of launching new products and services both in the digital health arena and within the mobile telecoms business. Phil started his career as a Chartered Accountant with Price Waterhouse before moving into consumer marketing and general management roles, in large to mid-sized companies. He holds an MA in Economics from the University of Cambridge and dual UK and Australian citizenship.

On his new appointment as CEO, Phil Offer says, “I am delighted to be joining the George Health, the commercial division of the George Institute, which has access to the entire Institute’s IP and builds clinically proven digital health products. I look forward to contributing to the George Health’s unique mission to reduce the social and financial burden of non-communicable diseases (NCDs) whilst delivering a competitive financial return for shareholders.”

The focus on non-communicable diseases is significant because there is a growing demand in large and underserved markets.  Worldwide there are 2 billion people, for instance, with cardiovascular disease, diabetes or hypertension and large proportions of the at-risk patients are not receiving appropriate care. This patient population is increasing due to ageing populations, shifting disease burdens, and healthcare resource constraints.

Regarding this search assignment, Coulter Partners’ Director, Geoff Dobson, adds, “This was a truly global search for a truly global role and we developed multiple candidate relationships, in multiple time zones. It took us from Europe to North America, to the Far East, including Singapore, Hong Kong and China, and to Australia. Two distinct candidate pools evolved – individuals from a software background that had moved into the healthcare sector, and senior individuals in the life sciences sector that had latterly moved into digital health. The George Institute’s huge reputation, in Australia and beyond, as an exceptional global team that is making a real difference to global health, drew strong lead candidates, among whom Phil was an outstanding choice. We wish him every success.”

About the George Institute for Global Health

The George Institute for Global Health is an internationally-recognised health research organisation, undertaking high-impact research across a broad landscape. The mission of the George is to improve the health of millions of people worldwide.  Affiliated with leading universities in Australia, China and the UK, the Institute is a global leader in research and policy on the prevention and treatment of common chronic and critical conditions such as diabetes, heart disease and severe trauma.

For further information please visit